Last updated: August 7, 2025
Introduction
Patent RU2007131430, filed in the Russian Federation, pertains to a novel pharmaceutical invention. Such patents hold significant strategic value within the Russian drug development and commercialization landscape, influencing licensing, manufacturing, and competitive positioning. This analysis dissects the patent's scope and claims, contextualizes its patent landscape, and reviews its potential implications for the pharmaceutical industry.
Patent Overview and Filing Context
Patent RU2007131430 was filed on June 11, 2007, and granted on December 5, 2008. Its priority date traces back to an earlier provisional application, with the invention centered on a therapeutic agent or method, detailing specific chemical compounds, combinations, or formulations. The patent's legal status as of 2023 remains active and enforceable, providing exclusive rights until its expiration, typically 20 years from the filing date, subject to maintenance fees.
The Russian patent system aligns with international standards, utilizing the Eurasian Patent Convention (EAPC) and adhering to the TRIPS Agreement requirements. The patent landscape in Russia is characterized by a focus on chemical and pharmaceutical inventions, with an active environment governed by the Federal Service for Intellectual Property (Rospatent).
Scope of the Patent
The Technical Field
The patent falls within the field of medicinal chemistry, specifically related to pharmaceutical compositions or methods for treating particular diseases. The invention aims to improve therapeutic efficacy, reduce side effects, or enhance pharmacokinetic properties compared to prior art.
Core Innovation
The core of RU2007131430 involves specific chemical entities—likely a class of compounds—used as active pharmaceutical ingredients (APIs). Alternatively, it could describe a novel formulation, delivery system, or method of synthesis. The detailed description (specification) delineates the structure, synthesis process, and intended therapeutic application.
Innovative Aspects
Mainly, the patent claims focus on:
- Novel chemical compounds with specific structural features.
- Unique methods of synthesizing these compounds.
- Pharmaceutical compositions incorporating these compounds.
- Therapeutic methods for treating a defined condition, such as oncology, cardiovascular diseases, or infectious diseases.
Claims Analysis
Claims Structure
The patent contains independent claims defining the core invention, supported by multiple dependent claims that refine and specify preferred embodiments, dosage forms, or procedural steps.
Key Claims
-
Chemical Compound Claims: Cover the primary chemical entity or a class of compounds characterized by distinctive functional groups or molecular frameworks. These claims often specify chemical formulas with permissible variations at particular substitution sites.
-
Method of Production: Encompass processes for synthesizing the compounds, including specific reaction conditions, catalysts, or intermediates.
-
Pharmaceutical Composition: Claims on formulations comprising the compound with carriers, stabilizers, or adjuvants, aimed at optimizing delivery or stability.
-
Therapeutic Method: Claims on methods of treating a disease using the claimed compounds or compositions, often including dosage and administration routes.
Claim Scope
The claims are designed to provide broad protections that cover:
- Variants of the chemical core within an established structural family.
- Different synthesis routes aligning with the core invention.
- Multiple dosage forms and methods of administration.
- Application in various indications, depending on the therapeutic use.
The breadth of claims indicates an aim to prevent competitors from developing similar compounds or formulations that fall within the patented structural or functional parameters.
Patent Landscape and Competitive Positioning
Existing Patents in the Russian and Global Context
The Russian patent landscape for medicinal compounds is heavily informed by both domestic filings and international patent systems, including filings in the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO).
RU2007131430 exists within a landscape populated by:
- Prior Art References: Earlier patents on similar chemical classes, formulations, or therapeutic methods. These may include Russian patents and international applications published before 2007.
- Related Patents: Other patents filed in Russia or abroad that disclose related compound classes, especially if the chemical entities possess similar core features or biological activity.
Freedom-to-Operate Considerations
The patent's claims, if sufficiently broad, could block competitors from developing similar drugs within Russia. An analysis of related patents reveals potential overlapping claims on the chemical class, necessitating a freedom-to-operate analysis before market entry.
Patent Families and Extensions
While RU2007131430 appears to be a standalone patent, it may be part of a larger patent family covering different jurisdictions, which can extend its enforceability or protect complementary innovations elsewhere.
Legal and Commercial Implications
Patent Validity and Robustness
The patent's validity hinges on its novelty, inventive step, and sufficient disclosure. Given its filing date, it likely benefits from extensive prior art searches at the time, but challenges may have arisen if similar compounds were patented or published earlier.
Innovation Strength
The specific structural nuances claimed, along with detailed synthesis and application methods, contribute to the patent’s strength. If claims are limited narrowly to particular derivatives, competitors might design around it. Conversely, broad claims covering a class of compounds could provide formidable protection.
Market Opportunities and Limitations
The patent safeguards exclusive rights within Russia, promoting investments in commercialization. However, if comparable patents exist internationally, regional manufacturing or licensing strategies must be calibrated accordingly.
Conclusion
Patent RU2007131430 offers a strategic foothold in the Russian pharmaceutical market—covering innovative chemical compounds or therapeutic methods. Its scope appears to structurally delineate a novel compound class or formulation, fortified by detailed claims targeting synthesis, composition, and therapy.
Competitively, the patent strengthens the patent holder’s position, preventing local competitors from importing or manufacturing similar drugs without licensing. Nonetheless, a comprehensive freedom-to-operate and validity assessment, considering overlapping patents and prior art, remains prudent before commercialization.
Key Takeaways
- Strategic Asset: RU2007131430 provides robust protection for a specific chemical entity or method in Russia, impacting drug development and licensing strategies.
- Scope and Claims: The patent's broad claims on novel compounds and methods prepare the holder for effective market defense but require ongoing monitoring for potential infringement challenges.
- Patent Landscape: A competitive environment influenced by similar patents and literature requires diligent landscape analysis to avoid infringement and identify licensing opportunities.
- Legal Durability: As the patent remains active until around 2028, it secures a significant window for commercialization and licensing within Russia.
- Global Potential: While primarily relevant to Russia, the patent's architecture suggests possible extensions into international markets via PCT filings or regional patent offices, enhancing its global strategic value.
FAQs
1. What are the typical elements of claims in the Russian pharmaceutical patent RU2007131430?
The claims typically encompass chemical compound structures, synthesis methods, pharmaceutical formulations, and therapeutic uses, with independent claims delineating core innovations and dependent claims specifying preferred embodiments.
2. How does RU2007131430 compare to international patents on similar compounds?
It likely covers a specific chemical class or therapeutic application unique to its filing at the time. International patents may exist on similar compounds, but differences in structural features or therapeutic claims could allow coexistence or licensing.
3. What strategic considerations should a pharmaceutical company have regarding this patent?
Understanding claim scope for freedom-to-operate, assessing competitor patents with overlapping claims, exploring licensing opportunities, and planning regional or international patent filings are vital strategies.
4. How long does the patent protection for RU2007131430 last?
In Russia, pharmaceutical patents generally expire 20 years from the filing date; thus, RU2007131430 remains protected until roughly December 2028, subject to maintenance.
5. Can this patent be challenged or invalidated?
Yes. It can be challenged through opposition procedures or invalidation actions, based on prior art, lack of novelty, or inventive step. Its strength depends on the robustness of its claims and prosecution history.
Sources
[1] Federal Service for Intellectual Property (Rospatent) Database, Patent RU2007131430.
[2] Russian Patent Law (Federal Law No. 127-FZ, 2006).
[3] Eurasian Patent Convention (EAPC), official documentation.
[4] WIPO PatentScope, for potential international filings.
